Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
MK-4830 (ILT4 Antagonist)
First-in-Class Anti-immunoglobulin – like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Other Articles & Publications
Clinical Cancer Research
June 2, 2022
,
Siu, et al.
No items found.
QS-21 STIMULON™ Adjuvant
Cancer Immunotherapy Targeting Tumour-Specific Antigens: Towards a New Therapy for Minimal Residual Disease.
Other Articles & Publications
Expert Opinion on Biological Therapy
June 2, 2022
,
Brichard, et al.
No items found.
INCAGN1949 (OX40 Agonist)
INCAGN01949: A Novel Anti-OX40 Agonist Antibody With the Potential to Enhance Tumor Specific T-cell Responsiveness, While Selectively Depleting Intratumoral Regulatory T Cells.
AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Gonzalez, et al.
No items found.
QS-21 STIMULON™ Adjuvant
Induction of Humoral and CD8+ T Cell Responses are Required for Protection Against Lethal Ebola Virus Infection.
Other Articles & Publications
The Journal of Immunology
June 2, 2022
,
Warfiled, et. al.
No items found.